Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Axin interactor, dorsalization associated (AIDA) is a multifunctional protein characterized by a unique C2 domain structure, enabling it to bind phosphoinositides and associate with membranes in a Ca(2+)-independent manner[1]. AIDA binds the axis formation inhibitor axin and inhibits axin-mediated Jun N-terminal kinase (JNK) activation, thereby antagonizing dorsalization during vertebrate embryonic development and promoting ventralization[1][2][3]. It plays roles in membrane dynamics, negative regulation of stress signaling pathways, and cytoskeletal anchoring. In humans, AIDA is implicated in cardiovascular disease via endothelial function regulation and may act as a biomarker in certain cancers, although there is no current evidence of it being targeted by drugs or serving as a direct therapeutic target[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Axin interactor, dorsalization associated (AIDA).